Could Ascendis Pharma A/S – American Depositary Shares (NASDAQ:ASND) Change Direction After More Shorts?

October 2, 2018 - By Adrian Mccoy

The stock of Ascendis Pharma A/S – American Depositary Shares (NASDAQ:ASND) registered an increase of 18.19% in short interest. ASND’s total short interest was 343,100 shares in October as published by FINRA. Its up 18.19% from 290,300 shares, reported previously. With 116,300 shares average volume, it will take short sellers 3 days to cover their ASND’s short positions. The short interest to Ascendis Pharma A/S – American Depositary Shares’s float is 1.57%.

The stock decreased 1.06% or $0.74 during the last trading session, reaching $68.93. About 33,375 shares traded. Ascendis Pharma A/S (NASDAQ:ASND) has risen 123.84% since October 2, 2017 and is uptrending. It has outperformed by 108.22% the S&P500.

Ascendis Pharma A/S, a clinical stage biopharmaceutical company, develops various prodrug therapies to treat unmet medical needs. The company has market cap of $2.88 billion. It is developing TransCon human growth hormone, which is in Phase III clinical study in children to treat growth hormone deficiency; and TransCon Treprostinil that is in Phase I clinical trial for the treatment of pulmonary arterial hypertension, a life-threatening disease characterized by elevated blood pressure in the pulmonary arteries. It currently has negative earnings. The firm is also developing TransCon Peptides for the treatment of diabetes; TransCon ranibizumab, a compound to support injection of ranibizumab in ophthalmology; TransCon parathyroid hormone for treating hypoparathyroidism; and TransCon C-type natriuretic peptide for the treatment of achondroplasia.

Ascendis Pharma A/S (NASDAQ:ASND) Ratings Coverage

Among 5 analysts covering Ascendis Pharma (NASDAQ:ASND), 4 have Buy rating, 0 Sell and 1 Hold. Therefore 80% are positive. Ascendis Pharma had 7 analyst reports since April 4, 2018 according to SRatingsIntel. The rating was maintained by Wedbush on Tuesday, May 15 with “Buy”. Leerink Swann maintained it with “Hold” rating and $7000 target in Thursday, May 31 report. The rating was maintained by Stifel Nicolaus on Thursday, August 30 with “Buy”. The rating was maintained by J.P. Morgan on Monday, May 14 with “Buy”. The firm has “Buy” rating given on Wednesday, April 4 by Wedbush.

More recent Ascendis Pharma A/S (NASDAQ:ASND) news were published by: Nasdaq.com which released: “Ascendis Pharma A/S Announces Presentations on Technology and Rare Disease Endocrinology Pipeline at …” on September 06, 2018. Also Globenewswire.com published the news titled: “Factors of Influence in 2018, Key Indicators and Opportunity within Ascendis Pharma A/S, Fluor, InterDigital, Ruth’s …” on September 27, 2018. Nasdaq.com‘s news article titled: “Ascendis Pharma A/S Announces Support for Children’s Growth Awareness Week and Day 2018” with publication date: September 17, 2018 was also an interesting one.

Ascendis Pharma A/S (NASDAQ:ASND) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


>